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As of March 2021, over 40 COVID-19 vaccine candidates were
either in phase 3 clinical trials or had received conditional approval
for emergency use [1]. The Pfizer/BioNTech, Moderna, Oxford/Astra-
Zeneca and Johnson and Johnson vaccines have been approved for
emergency use by multiple regulatory authorities. The Gamaleya
Sputnik-V, Sinopharm, Sinovac and CanSino vaccines have been
approved for emergency use in many countries though not yet by
stringent regulatory authorities. By April 2021, over 950 million vac-
cine doses had been administered worldwide but distribution hasLancet Commission on COVID-19 Vaccines and Therapeutics Task Force.
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1.1 doses/100 individuals in Africa [2,3].
The roll out of vaccines requires robust pharmacovigilance sys-
tems and global coordination of post-licensure surveillance [4]
including real-time information sharing, open source data repository
and a strong communication component. The WHO Global Vaccine
Safety Initiative aims to standardize reporting of adverse events fol-
lowing immunization (AEFI) and adverse events of special interest
(AESI) [5]. The WHO manual for COVID-19 vaccine safety surveillance
outlines the minimum requirements at global, regional and national
levels for passive surveillance with the ability to detect and investi-
gate AEFIs, safety signals or clustering events as well as determine
causality for defined AESI [6] Countries with well-established phar-
macovigilance systems are encouraged to establish active surveil-
lance to investigate AESIs through cohort monitoring, sentinel
surveillance or e-Health platforms.
It is plausible to envision that many well-established regulatory
authorities and pharmacovigilance platforms may be overwhelmed
by the sheer number of AEFIs reported over the next year as rollout
continues. The 2009 H1N1 swine flu influenza pandemic and vaccina-
tion roll out taught us that few countries’ pandemic preparednessr the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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vigilance platforms were unable to confirm or exclude associations
between AEFIs and the H1N1 vaccine and this contributed to eroding
vaccine confidence. Thus, global coordination with scientists, medical
and public health professionals, and pharmaceutical/manufacturing
companies, along with increased capacity to analyze and report real-
time events are of paramount importance to ensure robust pharma-
covigilance of COVID-19 vaccines [8].
By definition, very rare AEFIs (< 1/10.000) are usually not
detected prior to licensure but rather once vaccines are widely used
within a countries’ immunization programs. In the setting of global
COVID-19 vaccine introduction, extremely rare AEFIs such as throm-
bocytopaenia, disseminated intravascular coagulation, or cerebral
venous sinus thrombosis were identified and reported in some coun-
tries through their robust pharmacovigilance systems, confirming
that these systems work as expected. Based on these systems, regula-
tory bodies and advisory committees evaluate the data and risk-ben-
efit to make determinations of any changes in use. This can lead to
temporary pauses in vaccination for further evaluation, and/or to a
recommendation to add potential rare adverse events to the product
information.
Given the extensive global media coverage, accurate and wide-
spread communication is critical to convey complex messages relat-
ing to signal evaluation, causation and risk-benefit at a time when
news is increasingly consumed through the filters of social media
and internet search algorithms. Thus, robust and transparent phar-
macovigilance programs must be coupled with sophisticated com-
munication strategies and international efforts to combat vaccine
misinformation which can erode trust, create social discord and pro-
mote one vaccine over others for financial or political interests [9].
In addition to the standard vaccine safety surveillance issues,
COVID-19 vaccines pose additional challenges to post-licensure sur-
veillance, complicating the risk-benefit assessment of safety signals.
These include multiple authorized or approved vaccine types, poten-
tial interchangeability of vaccine types, dose interval flexibility and,
high comorbidities in the target population. Additional concerns may
emerge as the Covid19 vaccines are rolled out in low- and middle-
income countries (LMIC) where a high prevalence of malnutrition
and infectious diseases may impact the type of AEFIs and immune
responses observed in the context of less robust pharmacovigilance
programs. The Brighton Collaboration (https://brightoncollaboration.
us) global research safety vaccine network) has harmonized global
safety assessment tools and definitions for COVID-19 vaccines which
are regularly updated.
Challenges still lie ahead to ensure alignment, transparency and
interconnectivity across different systems and rapid feedback from
national to global level. This should involve broad stakeholders at
global as well as regional level. For example, the African Vaccine Reg-
ulatory Forum [10] pools regional resources, and such efforts may
increase resilience in areas of the world with less robust pharmacovi-
gilance systems.
The longer SARS-CoV-2 transmission is sustained, the higher the
probability that new variants emerge; potentially less sensitive to
existing vaccine protection. The global community thus finds itself
fully engaged in a race to reduce deaths and relieve pressure on
health systems but also to prevent community transmission and
emergence of new variants. It is still unclear how countries around
the world will collect, analyze and share real-world safety and effec-
tiveness data for subsequent decision-making. It should be stressed
to stakeholders, including governments, ministries of health and
international funders that investment in halting the COVID-19 pan-
demic does not stop at mass immunization. The timely generation
and dissemination of post-vaccination safety data will inform data-
driven policies, promote vaccine confidence, and accelerate establish-
ment of herd immunity necessary to end the COVID-19 pandemic.Declaration of Competing Interest
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